Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most （clusters of differentiation）CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells^[1]^[2].

References:

[1]. L Franco, et al. The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 1998 Nov;12(14):1507-20. [Content Brief]

[2]. Kumi Oshima, et al. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002 May 22;519(1-3):1-7. [Content Brief]

Transmembrane Glycoprotein Related Products (204):

By Effects:	Inhibitors (139) Ligands (2) Agonists (3) Antagonists (5) Activators (6) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990260

Anti-Mouse CD86/B7-2 Antibody (GL-1)	Inhibitor	99.17%
Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD86/B7-2. Anti-Mouse CD86/B7-2 Antibody (GL-1) can be used for the researches of inflammation and immunology, such as allergic pulmonary inflammation.

HY-P990607

Indatuximab	Inhibitor	98.04%
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990092

Rolistobart	Inhibitor
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic.

HY-P990496

Anti-PVRIG Antibody (COM701)	Inhibitor	99.14%
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-128128

ASN04421891	Modulator	99.00%
ASN04421891 is a potent GPR17 receptor modulator, with an EC₅₀ of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research.

HY-N8102

Echinocystic acid 28-O-β-D-glucoside	Inhibitor	99.11%
Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC₅₀ of 10.61 nM.

HY-P99674

Ivicentamab	Inhibitor	99.82%
Ivicentamab (GEN-3009) is an IgG1κ-type bispecific antibody targeting different epitopes of CD37. Ivicentamab can be used for cancer research.

HY-P991068

hT84.66-M5A	Inhibitor	99.03%
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99057A

Varlilumab (anti-CD27)	Inhibitor	99.68%
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

HY-P99381

XmAb 5592	Inhibitor	99.51%
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).

HY-P2511

Insulin β Chain Peptide (15-23)		98.03%
Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond.

HY-170589

GPR17 antagonist 1	Antagonist
GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity.

HY-P1822

BDC2.5 mimotope 1040-31	Agonist	98.00%
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg⁺T cells.

HY-157281

Photolumazine III		99.96%
Photolumazine III is a MHC class I related-1 molecule (MR1) antigen.

HY-P10551

ApoA-I mimetic peptide 5A	Inhibitor
ApoA-I mimetic peptide 5A is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). ApoA-I mimetic peptide 5A can promote the efflux of cholesterol from cells and help reduce the accumulation of cholesterol in cells. ApoA-I mimetic peptide 5A also shows anti-inflammatory activity and can reduce inflammatory markers in blood and tissues. ApoA-I mimetic peptide 5A can be used in the study of cardiovascular diseases.

HY-P990200

Anti-Mouse Ly6C Antibody (Monts 1)	Inhibitor
Anti-Mouse Ly6C Antibody (Monts 1) is a rat-derived anti-mouse Ly6C IgG2a type antibody inhibitor. Anti-Mouse Ly6C Antibody (Monts 1) depletes monocytes, neutrophils, and some other granulocyte populations. Anti-Mouse Ly6C Antibody (Monts 1) can be used for the researches of cancer, immunology and infection, such as chikungunya (CHIKV) and aggressive tumor.

HY-165245

SBI-183	Inhibitor	99.8%
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-P991108

Anti-CDH6/K-Cadherin Antibody	Inhibitor
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a human antibody expressed in CHO cells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-14921

Elsibucol	Inhibitor	99.35%
Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury.

HY-P990360

Anti-CD9 Antibody		99.52%
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Name
Email *

	Sorry, but the email address you supplied was invalid.